Chiusura precedente | 1,8300 |
Aperto | 1,8600 |
Denaro | 1,7200 x 400 |
Lettera | 1,7500 x 500 |
Min-Max giorno | 1,7000 - 1,9700 |
Intervallo di 52 settimane | 1,4500 - 180,9600 |
Volume | |
Media Volume | 1.478.037 |
Capitalizzazione | 9,694M |
Beta (5 anni mensile) | 1,49 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -49,9200 |
Prossima data utili | 07 mag 2024 - 13 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 720,00 |
First Drug Store Channel Retail Chain Begins VLN® Sales in September, Continues to Book Additional Launches for Rest of 2023BUFFALO, N.Y., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today announced its FDA authorized VLN® reduced nicotine content cigarettes designed specifically to promote tobacco h
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 62nd Emerging Growth Conference on September 6 & 7, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting com
BUFFALO, N.Y., Sept. 05, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ: XXII) (the “Company”) today announced that its Board of Directors, after consultation with its financial and legal advisors, has initiated a process to evaluate strategic alternatives with respect to the Company’s tobacco assets. The process will include consideration of a range of strategic, operational and financial transactions and alternatives, such as business combinations, asset sales, licensing agreements,